Aspire BioPharma is trading 6.5% up at $8.14 after filing a new investor presentation and presenting at the Sidoti Micro-Cap Virtual Investor Conference on August 19, 2026.
- Management highlighted its clinical and commercial pipeline and recently closed Dura Driver Control Systems acquisition, which generated investor interest.
- Broader biotech strength, including the sector’s 3.73% gain, is providing additional support.